

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

INSIDE INFORMATION ANNOUNCEMENT

PROPOSED PARTICIPATION IN THE H SHARE FULL CIRCULATION PILOT PROJECT BY THE COMPANY

This announcement is made by Shandong Weigao Group Medical Polymer Company Limited* (the “**Company**”) under the Inside Information Provisions of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”).

The Company is pleased to announce that, a formal approval letter from China Securities Regulatory Commission (the “**CSRC**”) on the application submitted by the Company to the CSRC in respect of the participation in the H share full circulation pilot project has been received on 10 July 2018 (the “**CSRC Approval**”). Pursuant to the CSRC Approval, the Company is allowed to convert and list up to 2,638,600,000 unlisted shares or domestic shares into H shares (the “**Conversion and Listing**”).

As at the date of this announcement, detailed implementation plan of the Conversion and Listing has not been finalized. The Company will make further announcement on the progress of the Conversion and Listing in compliance with the requirements under the Inside Information Provisions and the Listing Rules.

* For identification purpose only

The Conversion and Listing is still subject to the performance of other relevant procedures required by the Stock Exchange and other relevant onshore and offshore regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Zhang Hua Wei
Chairman

Weihai, Shandong, the PRC, 10 July 2018

As at the date hereof, the Board comprises of:

Mr. Zhang Hua Wei (*Executive Director*)

Mr. Wang Yi (*Executive Director*)

Mr. Gong Jian Bo (*Executive Director*)

Mrs. Zhou Shu Hua (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Ming Zhong (*Independent non-executive Director*)

Mrs. Wang Jin Xia (*Independent non-executive Director*)